Physician profile
Ignacio Mark Ramirez
NPI 1962536086
$1,287.85
in general payments reported to CMS, 2019-2025
23 companies · $746 in 2025
The $746 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $154 · 2023: $51.09 · 2024: $157 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $176.96 | 2021-2024 | Xtampza, Nucynta |
| Bayer Healthcare Pharmaceuticals INC. | $153.29 | 2024-2025 | |
| Novo Nordisk INC | $150.12 | 2025 | Wegovy, Ozempic |
| Abbvie INC. | $149.40 | 2021-2025 | |
| Pfizer INC. | $85.65 | 2025 | |
| Abbott Laboratories | $74.76 | 2024 | Proclaim |
| Grt US Holding, INC. | $67.93 | 2021-2022 | |
| Lilly USA, LLC | $65.92 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Antares Pharma, INC. | $53.69 | 2025 | Xyosted |
| Dexcom, INC. | $45.22 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.28 | 2021-2024 | Xifaxan |
| Hikma Pharmaceuticals USA | $36.56 | 2022 | |
| Corcept Therapeutics | $22.05 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $19.18 | 2025 | Auvelity |
| Braeburn INC. | $18.52 | 2023 | Brixadi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $17.56 | 2025 | NP Thyroid 60 |
| Exact Sciences Corporation | $17.04 | 2025 | The Cologuard Plus Collection Kit |
| Almatica Pharma LLC | $16.54 | 2021 | |
| Tolmar, INC. | $15.70 | 2025 | Jatenzo |
| Redhill Biopharma INC. | $15.67 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.11 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $14.38 | 2025 | Rexulti |
| Virtus Pharmaceuticals LLC | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.